<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577807</url>
  </required_header>
  <id_info>
    <org_study_id>LUMINOS-102</org_study_id>
    <nct_id>NCT04577807</nct_id>
  </id_info>
  <brief_title>LUMINOS-102: PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma</brief_title>
  <official_title>PVSRIPO in Combination With Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istari Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istari Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 study to investigate the efficacy and safety of PVSRIPO alone or in combination&#xD;
      with a programmed death receptor-1 (anti-PD-1) inhibitor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center, open-label, randomized, Phase 2 will investigate the efficacy and safety&#xD;
      of PVSRIPO alone (Arm 1) or in combination with an anti-PD-1 inhibitor (Arm 2). Following a 6&#xD;
      participant safety run-in period, up to approximately 50 participants with cutaneous or&#xD;
      mucosal melanoma who previously failed anti-PD-1/L1-based therapy will be randomized 1:1 to&#xD;
      receive either PVSRIPO or PVSRIPO plus an anti-PD-1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>The proportion of patients achieving confirmed complete (CR) or partial response (PR), per RECIST 1.1 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of treatment-emergent adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>The frequency and severity of treatment-emergent adverse events (TEAE) via Common Terminology Criteria for Adverse Events (CTCAE, v5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of adverse events of special interest (AESIs and AEs)</measure>
    <time_frame>24 months</time_frame>
    <description>PVSRIPO AESIs and anti-PD-1 immune related AEs (irAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of study treatment discontinuation due to adverse events (AEs)</measure>
    <time_frame>24 months</time_frame>
    <description>Study treatment discontinuation due to AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in the number of CD8+ tumor infiltrating lymphocytes (TILs)</measure>
    <time_frame>24 months</time_frame>
    <description>Changes from baseline in PD-L1 expression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival (OS): time from treatment group assignment until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>24 months</time_frame>
    <description>Duration of Response (DOR): time from confirmed objective response (CR or PR per RECIST 1.1) until unequivocal disease progression or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Disease control rate (DCR): the proportion of patients achieving confirmed CR, confirmed PR, or stable disease (SD) per RECIST1.1, as best response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR-6 months</measure>
    <time_frame>24 months</time_frame>
    <description>Disease control rate-6months (DCR-6mo): the proportion of patients achieving confirmed CR (any duration), confirmed PR (any duration) or SD (≥ 6 months) per RECIST 1.1 as best response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durable Response Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Durable Response Rate (DRR): the proportion of participants with confirmed CR or PR (per RECIST 1.1) lasting at least 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Progression-free survival (PFS): time (number of months) from treatment group assignment until date of documented radiologic disease progression per RECIST 1.1 or death due to any cause, whichever comes first</description>
  </secondary_outcome>
  <other_outcome>
    <measure>PVSRIPO mechanism of action and predictors of response to PVSRIPO with or without anti-PD-1 in patients who have failed anti-PD1/L1 -based therapy</measure>
    <time_frame>24 months</time_frame>
    <description>Assessment and identification of genetic, cytologic, histologic and/or other markers in tumor biopsies and PBMC samples that may correlate with response.&#xD;
Assessment of changes over time in immune markers, including, but not limited to immune cell density, T cell receptor repertoire, and chemokine and/or cytokine profile in blood, samples, and/or tissue</description>
  </other_outcome>
  <other_outcome>
    <measure>ORR based on iRECIST</measure>
    <time_frame>24 months</time_frame>
    <description>ORR based on iRECIST criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>DOR based on iRECIST</measure>
    <time_frame>24 months</time_frame>
    <description>DOR based on iRECIST criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>DRR based on iRECIST</measure>
    <time_frame>24 months</time_frame>
    <description>DRR based on iRECIST criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>DCR based on iRECIST</measure>
    <time_frame>24 months</time_frame>
    <description>DCR based on iRECIST criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>DCR-6mo based on iRECIST</measure>
    <time_frame>24 months</time_frame>
    <description>DCR-6mo based on iRECIST criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>ORR based on subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>ORR in the following subgroups:&#xD;
Acquired versus primary PD-1/L1 resistance as defined by Kluger, et al (2020)&#xD;
BRAF wild type and mutant&#xD;
LDH levels at baseline&#xD;
Time since last dose of anti-PD1/L1 therapy prior to randomization (≤ or &gt;6 weeks)&#xD;
Crossover to combination arm from PVSRIPO monotherapy</description>
  </other_outcome>
  <other_outcome>
    <measure>DOR based on subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>DOR in the following subgroups:&#xD;
Acquired versus primary PD-1/L1 resistance as defined by Kluger, et al (2020)&#xD;
BRAF wild type and mutant&#xD;
LDH levels at baseline&#xD;
Time since last dose of anti-PD1/L1 therapy prior to randomization (≤ or &gt;6 weeks)&#xD;
Crossover to combination arm from PVSRIPO monotherapy</description>
  </other_outcome>
  <other_outcome>
    <measure>DRR based on subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>DRR in the following subgroups:&#xD;
Acquired versus primary PD-1/L1 resistance as defined by Kluger, et al (2020)&#xD;
BRAF wild type and mutant&#xD;
LDH levels at baseline&#xD;
Time since last dose of anti-PD1/L1 therapy prior to randomization (≤ or &gt;6 weeks)&#xD;
Crossover to combination arm from PVSRIPO monotherapy</description>
  </other_outcome>
  <other_outcome>
    <measure>DCR based on subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>DCR in the following subgroups:&#xD;
Acquired versus primary PD-1/L1 resistance as defined by Kluger, et al (2020)&#xD;
BRAF wild type and mutant&#xD;
LDH levels at baseline&#xD;
Time since last dose of anti-PD1/L1 therapy prior to randomization (≤ or &gt;6 weeks)&#xD;
Crossover to combination arm from PVSRIPO monotherapy</description>
  </other_outcome>
  <other_outcome>
    <measure>DCR-6mo based on subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>DCR-6mo in the following subgroups:&#xD;
Acquired versus primary PD-1/L1 resistance as defined by Kluger, et al (2020)&#xD;
BRAF wild type and mutant&#xD;
LDH levels at baseline&#xD;
Time since last dose of anti-PD1/L1 therapy prior to randomization (≤ or &gt;6 weeks)&#xD;
Crossover to combination arm from PVSRIPO monotherapy</description>
  </other_outcome>
  <other_outcome>
    <measure>OS based on subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>OS in the following subgroups:&#xD;
According to treatment arm and AJCC stage at baseline&#xD;
Primary versus acquired resistance as defined by Kluger et al&#xD;
BRAF wild type and mutant&#xD;
LDH levels at baseline&#xD;
Time since last dose of anti-PD1/L1 therapy prior to randomization (≤ or &gt;6 weeks)&#xD;
Crossover to combination arm from PVSRIPO monotherapy</description>
  </other_outcome>
  <other_outcome>
    <measure>PFS based on subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>PFS in the following subgroups:&#xD;
According to treatment arm and AJCC stage at baseline&#xD;
Primary versus acquired resistance as defined by Kluger et al&#xD;
BRAF wild type and mutant&#xD;
LDH levels at baseline&#xD;
Time since last dose of anti-PD1/L1 therapy prior to randomization (≤ or &gt;6 weeks)&#xD;
Crossover to combination arm from PVSRIPO monotherapy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm 1: PVSRIPO Only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PVSRIPO (up to 6x10^8 TCID50) administered via direct injection to amenable melanoma lesions given every 3 or 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: PVSRIPO and anti-PD-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PVSRIPO (up to 6x10^8 TCID50) administered via direct injection to amenable melanoma lesions and anti-PD-1 therapy given every 3 or 4 weeks as per the anti-PD-1 approved package insert</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PVSRIPO</intervention_name>
    <description>PVSRIPO administered via direct lesion injection</description>
    <arm_group_label>Arm 1: PVSRIPO Only</arm_group_label>
    <arm_group_label>Arm 2: PVSRIPO and anti-PD-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-PD-1 Checkpoint Inhibitor</intervention_name>
    <description>Anti-PD-1 Checkpoint Inhibitor administered per package insert instructions</description>
    <arm_group_label>Arm 2: PVSRIPO and anti-PD-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 18 years of age&#xD;
&#xD;
          2. Prior CDC-recommended vaccination series against PV, and has received a boost&#xD;
             immunization with trivalent IPOL® (Sanofi-Pasteur SA) at least 1 week, but less than 6&#xD;
             weeks, prior to Day 1&#xD;
&#xD;
             a. NOTE: Patients who are unsure of their vaccination status must provide evidence of&#xD;
             anti-PV immunity prior to enrollment, as applicable&#xD;
&#xD;
          3. Has biopsy proven unresectable cutaneous, acral or mucosal melanoma and is willing to&#xD;
             undergo tumor biopsy prior to the first dose of study drugs and at prespecified&#xD;
             intervals during the study (see Table 1).&#xD;
&#xD;
               1. Submission of an archival biopsy sample is allowed in lieu of the baseline tumor&#xD;
                  biopsy, provided the tissue is ≤4 months old and the participant received no&#xD;
                  intervening systemic/intratumoral anti-cancer therapy since the biopsy was&#xD;
                  acquired.&#xD;
&#xD;
               2. Must have at least 1 lesion that is amenable to biopsy. The lesion must be safely&#xD;
                  accessible as determined by the investigator and should not be located at sites&#xD;
                  that require significant risk procedures to biopsy. Examples of sites considered&#xD;
                  to be of significant risk include but are not limited to the following: the&#xD;
                  brain, lung, mediastinum, pancreas, or endoscopic procedures extending beyond the&#xD;
                  esophagus, stomach, or bowel wall.&#xD;
&#xD;
          4. Has ≥ 2 melanoma lesions that are accurately measurable by caliper or a radiological&#xD;
             method according to RECIST 1.1 criteria&#xD;
&#xD;
               1. One lesion must be injectable- defined as a visible or palpable cutaneous,&#xD;
                  subcutaneous, or nodal melanoma lesion ≥10 mm in longest diameter or multiple&#xD;
                  injectable melanoma lesions which in aggregate have a longest diameter of ≥10 mm&#xD;
                  and where the minimum lesion size is ≥5 mm&#xD;
&#xD;
               2. Note that visceral lesions (eg, liver, lung, retroperitoneal, subpleural lesions)&#xD;
                  are not considered injectable for the purposes of this trial.&#xD;
&#xD;
          5. Has confirmed disease progression per iRECIST after receiving at least 6 weeks of&#xD;
             treatment with an FDA-approved anti-PD-1/L1 therapy (as monotherapy or in combination)&#xD;
             without experiencing a toxicity requiring permanent discontinuation of the&#xD;
             anti-PD-1/L1. Patients treated with anti-PD-1/L1 in the adjuvant setting and who have&#xD;
             confirmed progression after at least 6 weeks of anti-PD-1/L1 therapy are allowed.&#xD;
&#xD;
             a. NOTE: Patients with known BRAF mutation must have also failed or refused to receive&#xD;
             BRAF-targeted therapy (alone or in combination with MEK inhibitor) to be eligible.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) status of 0-1&#xD;
&#xD;
          7. Serum lactate dehydrogenase (LDH) levels ≤ 3 x upper limit of normal (ULN)&#xD;
&#xD;
          8. Adequate bone marrow, liver and renal function as assessed by the following:&#xD;
&#xD;
               1. Hemoglobin ≥ 9.0 g/dl, patients may be transfused&#xD;
&#xD;
               2. Lymphocyte count ≥ 0.5 x 10^9/L (500 µL)&#xD;
&#xD;
               3. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1500 µL)&#xD;
&#xD;
               4. Platelet count ≥ 100 x 10^9/L (100,000 µL) without transfusion&#xD;
&#xD;
               5. AST, ALT, and alkaline phosphatase (ALP) ≤ 2.5 x upper limit of normal (ULN),&#xD;
                  with the following exceptions: Patients with documented liver metastases: AST and&#xD;
                  ALT ≤ 5 x ULN; Patients with documented liver or bone metastases: ALP ≤ 5 x ULN&#xD;
&#xD;
               6. Serum bilirubin ≤ 1.5 x ULN with the following exception: Patients with known&#xD;
                  Gilbert disease: serum bilirubin level ≤ 3 x ULN&#xD;
&#xD;
               7. Measured or calculated (per institutional standards) creatinine clearance ≥ 30&#xD;
                  ml/min (GRF can also be used in place of creatinine clearance)&#xD;
&#xD;
               8. For patients not receiving therapeutic anticoagulation: INR, PT, PTT (or aPTT) ≤&#xD;
                  1.5 x ULN&#xD;
&#xD;
          9. Life expectancy of &gt;12 weeks&#xD;
&#xD;
         10. Signed informed consent form (ICF) indicating that participant understands the purpose&#xD;
             of, and procedures required for the study, and is willing/able to participate in the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has biopsy-proven ocular melanoma&#xD;
&#xD;
          2. Symptomatic, untreated, or actively progressing central nervous system (CNS)&#xD;
             metastases. Participants with a history of treated CNS lesions are eligible, provided&#xD;
             the following criteria are met:&#xD;
&#xD;
               1. No stereotactic radiotherapy within 7 days, or whole-brain radiotherapy within 14&#xD;
                  days of Day 1&#xD;
&#xD;
               2. No ongoing requirement for corticosteroids to manage CNS disease. Anticonvulsant&#xD;
                  therapy at a stable dose is permitted.&#xD;
&#xD;
               3. Asymptomatic patients with CNS metastases newly detected at screening are&#xD;
                  eligible for the study after receiving radiotherapy or surgery, with no need to&#xD;
                  repeat the screening brain scan&#xD;
&#xD;
          3. History of leptomeningeal disease&#xD;
&#xD;
          4. Uncontrolled tumor-related pain. Participants requiring pain medication must be on a&#xD;
             stable regimen at study entry.&#xD;
&#xD;
               1. Symptomatic lesions amenable to palliative radiotherapy (e.g., bone metastases or&#xD;
                  metastases causing nerve impingement) should treated prior to enrollment.&#xD;
                  Patients should be recovered from the effects of radiation. There is no required&#xD;
                  minimum recovery period&#xD;
&#xD;
               2. Asymptomatic metastatic lesions that would likely cause functional deficits or&#xD;
                  intractable pain with further growth (e.g., epidural metastasis that is not&#xD;
                  currently associated with spinal cord compression) should be considered for&#xD;
                  loco-regional therapy if appropriate prior to enrollment&#xD;
&#xD;
          5. Uncontrolled pleural effusion, pericardial effusion, or ascites a. Patients with&#xD;
             indwelling catheters (e.g., PleurX™) are allowed.&#xD;
&#xD;
          6. Active or history of autoimmune disease or immune deficiency within previous 2 years,&#xD;
             with the following exceptions:&#xD;
&#xD;
               1. History of autoimmune-related hypothyroidism that is managed by thyroid&#xD;
                  replacement hormone&#xD;
&#xD;
               2. Type 1 diabetes mellitus that is well-controlled by an established insulin&#xD;
                  regimen&#xD;
&#xD;
               3. Eczema, psoriasis, or lichen simplex chronicus with dermatologic manifestations&#xD;
                  only (e.g., patients with psoriatic arthritis are excluded), provided all of the&#xD;
                  following conditions are met:&#xD;
&#xD;
             i. Rash must cover &lt;10% of body surface area&#xD;
&#xD;
             ii. Disease is well-controlled at baseline and requires only low-potency topical&#xD;
             corticosteroids&#xD;
&#xD;
             iii. No occurrence of acute exacerbations of the underlying condition requiring&#xD;
             psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral&#xD;
             calcineurin inhibitors, or high potency or oral corticosteroids within 12 months of&#xD;
             Day 1&#xD;
&#xD;
          7. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis&#xD;
             obliterans), drug-induced or idiopathic pneumonitis, or evidence of active pneumonitis&#xD;
             on screening chest computed tomography (CT) scan&#xD;
&#xD;
             a. History of radiation pneumonitis in the radiation field (fibrosis) is allowed.&#xD;
&#xD;
          8. History of a positive HIV RNA test (HIV 1 or 2 RNA by PCR)&#xD;
&#xD;
          9. Known active hepatitis B virus (HBV) infection (chronic or acute)&#xD;
&#xD;
             a. NOTE: Participants with a negative HBsAg test and a positive total hepatitis B core&#xD;
             antibody (HBcAb) test are allowed.&#xD;
&#xD;
         10. Known active hepatitis C virus (HCV) infection&#xD;
&#xD;
             a. NOTE: History of a positive HCV antibody test, but negative HCV RNA test is&#xD;
             allowed.&#xD;
&#xD;
         11. Active tuberculosis&#xD;
&#xD;
         12. Significant cardiovascular disease, such as New York Heart Association Class II or&#xD;
             greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3&#xD;
             months of Day 1, unstable arrhythmia, or unstable angina&#xD;
&#xD;
         13. Has received prior systemic anti-cancer therapy including investigational agents&#xD;
             within 4 weeks or 5 elimination half-lives- whichever is shorter, prior to treatment,&#xD;
             or has not recovered from all AEs due to previous therapies to ≤Grade 1 or baseline.&#xD;
             Participants with ≤Grade 2 neuropathy are eligible&#xD;
&#xD;
               1. Note: Anti-PD-1/L1 within 4 weeks prior to Day 1 is allowed&#xD;
&#xD;
               2. If participant received major surgery, they must have recovered adequately from&#xD;
                  the toxicity and/or complications from the intervention prior to starting study&#xD;
                  treatment.&#xD;
&#xD;
         14. History of other malignancy within 2 years of Day 1, with the exception of those with&#xD;
             a negligible risk of metastasis or death (e.g., resected cutaneous basal cell&#xD;
             carcinoma, or other cancers with 5-year OS of &gt;90%)&#xD;
&#xD;
         15. Severe infection within 4 weeks of Day 1, including, but not limited to,&#xD;
             hospitalization for complications of infection, bacteremia, or severe pneumonia&#xD;
&#xD;
             a. Prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic&#xD;
             obstructive pulmonary disease exacerbation) are allowed.&#xD;
&#xD;
         16. Prior allogeneic stem cell or solid organ transplantation&#xD;
&#xD;
         17. Treatment with a live, attenuated vaccine within 4 weeks of Day 1&#xD;
&#xD;
         18. Treatment with systemic immunosuppressive medication within 4 weeks of Day 1, with the&#xD;
             following exceptions:&#xD;
&#xD;
               1. Participants who received acute, low-dose systemic immunosuppressant medication&#xD;
                  or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours&#xD;
                  of corticosteroids for a contrast allergy) are eligible&#xD;
&#xD;
               2. Patients receiving mineralocorticoids (e.g., fludrocortisone), or systemic&#xD;
                  prednisone equivalent corticosteroid doses of &lt;10mg per day are eligible for the&#xD;
                  study&#xD;
&#xD;
         19. Known hypersensitivity to pembrolizumab, nivolumab, or any of the respective&#xD;
             excipients&#xD;
&#xD;
         20. Requires therapeutic anticoagulation and cannot discontinue anticoagulation safely&#xD;
             during the day prior, day of, and day after each PVSRIPO injection&#xD;
&#xD;
             a. NOTE: Participants receiving anticoagulation with warfarin at the time of study&#xD;
             entry are allowed if they can be transitioned to an alternative anticoagulant (eg, low&#xD;
             molecular weight heparin or direct oral anticoagulants) prior to the first dose of&#xD;
             PVSRIPO. Anyone transitioned from warfarin to an oral anticoagulant prior to the first&#xD;
             dose of PVSRIPO should have an INR &lt;1.5x upper limit of normal in order to&#xD;
             participate. Antiplatelet agents (eg, aspirin, clopidogrel, etc.) are not considered&#xD;
             anticoagulants for the purposes of this study (ie, are allowed)&#xD;
&#xD;
         21. A pregnant or nursing female, or women of child-bearing potential and men who are&#xD;
             sexually active and not willing/able to use medically acceptable forms of&#xD;
             contraception starting from signed ICF through 150 days after last anti-PD-1 dose&#xD;
&#xD;
         22. History of human serum albumin allergy&#xD;
&#xD;
         23. History of neurological complications due to polio virus infection&#xD;
&#xD;
         24. History of agammaglobulinemia&#xD;
&#xD;
         25. Concurrent participation in a separate interventional clinical trial during this&#xD;
             study.&#xD;
&#xD;
         26. Any underlying medical condition for which, in the opinion of the investigator,&#xD;
             participation would not be in the best interest of the participant (e.g., compromises&#xD;
             the participant's well-being) or that could prevent, limit, or confound&#xD;
             protocol-specified assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Istari Clinical</last_name>
    <phone>919-245-7662</phone>
    <email>InfoLUMINOS-102@IstariOncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Irvine Medical Center, Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Health U7 Health Cancer Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America</name>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <zip>60099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Community Cancer Center North Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OncoBay</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncobay</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48335</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
    </contact>
    <contact_backup>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland, Seidman Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University, James Cancer Hospital and Solove Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Rockledge</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology -Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University Medical Center</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istari Clinical</last_name>
      <email>InfoLUMINOS-102@IstariOncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

